View Featured Offers >>

CST Wins CiteAb 2023 Innovation Award for Anti-CAR Linker Antibodies for T-Cell Therapy, Named PTM Antibody Supplier of the Year

CST was also Highly Commended in CiteAb's Antibody Supplier of the Year category

Danvers, MA, USA, May 4, 2023Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced that it was recognized in three categories in the 2023 CiteAb Awards, which highlight the best suppliers and individuals in the research reagent sector worldwide.

CST was recognized in the following categories:

  • The Innovation Award: Awarded to a product that has satisfied a gap in the market or solved a known issue within the respective field. CST was selected by a judging panel consisting of life scientists working in industry and academia and received The Innovation Award for the company's new anti-CAR linker antibodies, which help streamline the development and optimization of chimeric antigen receptors (CAR) for T-cell therapy research.
  • Post Translational Modification (PTM) Antibody Supplier of the Year: Granted to the antibody supplier with the most citations for PTM antibodies, CST was recognized after an analysis of CiteAb's antibody database of open-access and subscription-only scientific journals.
  • Antibody Supplier of the Year: CST was Highly Commended in this category based on the high number of citations received for its antibody products.

CST® anti-CAR linker antibodies fill a critical gap in the development of immuno-oncology treatments. CAR-T cell therapy is a revolutionary new cancer treatment that uses the patient's own immune cells to target their tumor. However, to ensure the treatment effectiveness, unique CAR-T detection reagents are needed to monitor CAR surface expression during pre-clinical research.

By targeting the linker sequence used in CAR-T cells, anti-CAR linker antibodies are a powerful tool to facilitate, accelerate, and standardize cell therapy research and development by eliminating the lengthy and expensive process of designing specific reagents to target individual CAR surface receptors. Designed and validated by CST scientists working on the cutting edge of research, this innovative technology enables the faster, more cost-effective development of life-saving cancer treatments.

Dr Andrew Chalmers, CEO and founder of CiteAb said, "We are thrilled to award Cell Signaling Technology with the Innovation Award for this product. Anti-CAR linker antibodies have the potential to create a really positive impact in cancer research. We were really excited to learn more about how the product has offered a solution to challenges in this field.”

PTMs, such as phosphorylation, acetylation, ubiquitylation, and others, are vital ways in which proteins communicate within cells. Understanding signaling pathways and developing sensitive, reliable anti-PTM antibodies have been a core focus of CST's research and development since the company's founding, and the company provides antibodies to detect PTMs at multiple locations on a given protein. CST is also the developer of the PhosphoSitePlus® database, a free, online resource with human-curated data about PTMs and their locations for thousands of proteins.

Rhys Williams, Senior Product Manager for CiteAb antibody data, said: "By producing quality PTM antibodies, Cell Signaling Technology is helping to support research into cell biology and disease, with examples ranging from neurodegenerative diseases, to cancer and heart disease. We want to extend a massive congratulations to Cell Signaling Technology for their win in this award!”

CST has a long history of strong performance in awards and recognition by CiteAb, including being named the Antibody Supplier of the Decade in 2020, as well as the Supplier Succeeding in Cancer Research and Recombinant Antibody Supplier of the Year in 2022. Additionally, according to CiteAb's most recent Top 100 Cited Antibodies report, eight of the 12 most-cited antibodies are from CST, and over one-third of the list are CST products-more than any other supplier.

Learn more about CiteAb and the 2023 Awards by visiting:

About CiteAb

CiteAb provides world-class data that accelerates scientific research. Our industry- leading data collection technology combines machine learning and extensive human reviewing to identify and understand reagent use from scientific publications. This highly accurate data is used to power all of our products, which help researchers find and suppliers sell the best reagents. Our search engine ranks products by citations, fundamentally changing the way researchers find products for their experiments, and our data-based products are used to inform suppliers globally. Over 4 million pages of information were served to CiteAb users in the last year, from searches of over 6.8 million reagents. We are a committed group of biologists and computer scientists dedicated to helping the world's best scientists and suppliers tackle the big problems in life science research. For more information, visit

About Cell Signaling Technology

Cell Signaling Technology (CST) is a different kind of life science company—one founded, owned, and run by active research scientists, with the highest standards of product and service quality, technological innovation, and scientific rigor. Founded in 1999 and headquartered in Danvers, Massachusetts, USA, CST employs over 600 people worldwide. We consistently provide fellow scientists around the globe with best-in-class products and services to fuel their quests for discovery. CST is a company of caring people driven by a devotion to facilitating good science—a company committed to doing the right thing for our Customers, our communities, and our planet.

CST Media and Press

Rebecca J. Reppucci, MBA
Cell Signaling Technology, Inc.
Senior Director, Global MarComm & Technology
Phone: 978-880-3334
email: [email protected]